GSTM1 and anemia: A research paper in 2009 that studied post-PCI anemia (defined as Hb <10g/dL) reported that 8.8% of patients developed post-PCI anemia, which was associated with a greater incidence of death at six months (6.5% vs. 1.7%), six-month major adverse cardiovascular event (recurrent MI or target vessel revascularization; 27.3% vs. 14.5%), and long-term mortality (25.8% vs. 8.7%) [55].